Table 2. Efficacy of daily ibrutinib in mantle cell lymphoma 3.
|
Ibrutinib 560 mg (111 patients) |
|
|---|---|
| Overall response rate# | 68% (23 complete responses, 52 partial responses) |
| Estimated median duration of progression-free survival | 17.5 months |
| Estimated median progression-free survival | 13.9 months |
| Estimated overall survival at 18 months | 58% |
# Response was assessed by regular physical and radiological examinations (CT and PET scans) and bone marrow biopsy. A PET scan was needed to confirm complete responses.